Rapport Therapeutics Quarterly Cash Flow Statement
NASDAQ: RAPPHealth CareBiotechnology: Pharmaceutical PreparationsUSD
30.65+0.80 (+2.68%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Rapport Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Rapport Therapeutics generated -$41.5 million of operating cash flow and spent $78,000 on capital expenditures. That left free cash flow of -$41.5 million.
Summary generated from market data by MetaCap's automated system. Methodology
Rapport Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -56.62M | -19.86M | -33.76M | -26.93M | -26.73M | -24.06M | -19.98M | -17.54M | -18.12M | -22.67M | -13.52M | -8.71M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 212.00K | 227.00K | 265.00K | 256.00K | 252.00K | 244.00K | 260.00K | 219.00K | 208.00K | 152.00K | 53.00K | 23.00K |
| Stock-Based Compensation | 7.20M | 6.96M | 5.69M | 4.74M | 4.39M | 4.04M | 3.21M | 3.18M | 2.35M | 1.49M | 998.00K | 859.00K |
| Change in Working Capital | -3.91M | 2.59M | 1.30M | -541.00K | 534.00K | 134.00K | 680.00K | 46.00K | 118.00K | -1.11M | 610.00K | 657.00K |
| Operating Cash Flow | -41.45M | -13.06M | -24.70M | -17.46M | -25.07M | -20.24M | -14.45M | -16.41M | -16.35M | -17.61M | -10.36M | -5.42M |
| Capital Expenditures | -78.00K | -86.00K | -169.00K | -134.00K | -22.00K | -291.00K | -226.00K | -140.00K | -967.00K | -1.07M | -1.44M | -52.00K |
| Investing Cash Flow | 25.60M | 37.94M | -174.32M | -56.78M | 22.60M | 21.03M | 31.93M | -53.04M | -107.10M | -41.93M | -78.66M | -52.00K |
| Financing Cash Flow | 1.41M | 531.00K | 311.00K | 270.53M | -63.00K | 5.00K | 7.00K | -1.39M | 159.35M | 63.66M | -140.00K | 85.36M |
| Net Change in Cash | -14.44M | 25.41M | -198.71M | 196.29M | -2.54M | 799.00K | 17.49M | -70.85M | 35.90M | 4.12M | -89.16M | 79.88M |
| Free Cash Flow | -41.53M | -13.15M | -24.87M | -17.60M | -25.09M | -20.53M | -14.67M | -16.55M | -17.32M | -18.69M | -11.79M | -5.48M |
This table shows 12 quarterly periods of Rapport Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RAPP's reporting calendar. What is a cash flow statement?